Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marriott International Inc (MAR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Marriott International Inc Trade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Marriott International Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Marriott International Inc trades at $367.9 (market cap $96.76B), while Vertex Pharmaceuticals Incorporated trades at $481.57 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Marriott International Inc pays a 0.8% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

MARVRTX
Market Cap
$96.76B$121.95B
Sector
Consumer CyclicalHealth
52-Week High
$402.54$529.59
52-Week Low
$255.35$366.54
Enterprise Value
$113.71B$116.69B
Dividend Yield
0.8%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marriott International Inc

No Aura AI signal available yet.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.

The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marriott International Inc

Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.

Read more on MAR

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX